跳至主要内容
临床试验/EUCTR2005-002068-27-AT
EUCTR2005-002068-27-AT进行中(未招募)1 期

Prevention of venous thrombosis in cancer patients: A prospective, randomized, double-blind study comparing two different dosages of low-molecular weight heparin

Medical University of Vienna0 个研究点目标入组 94 人开始时间: 2006年3月16日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
94

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients (> 18 years) with active cancer and at least one of the following indications for thromboprophylaxis with LMWH:
  • immobilization
  • history of VTE
  • acute inflammation
  • heart failure
  • respiratory failure
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • indication for LMWH or UFH at therapeutic dosages (e.g. for acute venous thromboembolism)
  • treatment with antithrombotics (vitamin K antagonists, acetylsalicylic acid, clopidogrel) for reasons other than prevention of VTE (e.g. atrial fibrillation, myocardial infarction)
  • contraindication for the treatment with LMWH
  • surgery within the last 4 weeks
  • thrombocytopenia (< 100.000/µl)
  • prolonged prothrombin time
  • prolonged activated partial thromboplastin time (aPTT)
  • history of heparin-induced thrombocytopenia
  • bodyweight < 50 kg or > 100 kg
  • renal insufficiency (creatinine ? 2 mg/dl)

研究者

相似试验